Skip to main content

Table 2 Tumor response and outcomes of the 92 patients

From: Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma

 

CCRT (n = 25)

Chemotherapy (n = 67)

p-value

Capecitabine plus cisplatin chemotherapy, total cycles (mean ± SD)

5.6 ± 5.8

4.0 ± 3.2

0.082

Tumor response (n = 90), n (%)

  

0.365

 CR

0 (0)

0 (0)

 

 PR

1 (4.0)

3 (4.6)

 

 SD

13 (52.0)

24 (36.9)

 

 PD

11 (44.0)

38 (58.5)

 

 Disease-control rate (CR + PR + SD)

14 (56.0)

27 (41.5)

0.217

Median FU duration, months (IQR)

7.4 (4.1 – 15.1)

4.1 (2.3 – 8.3)

0.044

Median PFS, months (95% CI)

4.3 (3.3 – 5.4)

1.9 (1.3 – 2.4)

0.001*

Median OS, months (95% CI)

9.3 (7.6 – 11.0)

6.2 (4.1 – 8.2)

0.162*

  1. *By log-rank test.